Business
biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement
biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n \n biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement\n \n \nbiOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 21, 2015) - biOasis (OTCQX:BIOAF)(TSX VENTURE:BTI) and Brigham and Women's Hospital Inc. (\"BWH\"), Harvard Medical School's distinguished teaching hospital, have entered into a collaboration to pursue work in the area of neuro-oncology. \n Dr. Sean Lawler, researcher in the Department of Neurosurgery, Harvard Medical School, will lead the BWH team.\n The collaboration intends to initially focus on the advancement to clinic of the Transcend peptide carrier, MTfp, including MTfp-TZM, MTfp-siRNA and MTfp-miRNA within GBM (glioblastoma) models. \n BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF)(TSX VENTURE:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it is entered into a Research Collaboration Agreement with Brigham and Women's Hospital Inc.\n Using biOasis's Transcend Platform peptide carrier, MTfp, biOasis and researchers lead by Dr. Sean Lawler from the Department of Neurosurgery, Harvard Medical School, will work to deliver a number of compounds targeting glioblastoma tumors within the brain. The initial focus of the collaboration will be on the compounds, MTfp-TZM, MTfp-siRNA and MTfp-miRNA. The work will include moving the trastuzumab program forward towards human clinical trials.\n A major teaching hospital of Harvard Medical School, Brigham and Women's Hospital was formed in 1980 with the merger of the Peter Bent Brigham Hospital, the Robert Breck Brigham Hospital, and the Boston Hospital for Women, three of Boston's oldest and most prestigious Harvard Medical School teaching hospitals. The BWH website states that, \"The BWH Research Institute (BRI) is one of the most powerful biomedical research institutes in the world and the second largest recipient of National Institutes of Health (NIH) funding among independent hospitals in the United States.\"\n Rob Hutchison, biOasis CEO, stated, \"biOasis's Transcend Platform and our peptide carrier, MTfp, have shown exceptional promise in the area o...